Country: United States
Language: English
Source: NLM (National Library of Medicine)
NEOSTIGMINE METHYLSULFATE (UNII: 98IMH7M386) (NEOSTIGMINE - UNII:3982TWQ96G)
Fresenius Kabi USA, LLC
NEOSTIGMINE METHYLSULFATE
NEOSTIGMINE METHYLSULFATE 0.5 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. Neostigmine is contraindicated in patients with: - known hypersensitivity to neostigmine methylsulfate (known hypersensitivity reactions have included urticaria, angioedema, erythema multiforme, generalized rash, facial swelling, peripheral edema, pyrexia, flushing, hypotension, bronchospasm, bradycardia and anaphylaxis). - peritonitis or mechanical obstruction of the urinary or intestinal tracts. Risk Summary There are no adequate or well-controlled studies of Neostigmine Methylsulfate Injection in pregnant women. It is not known whether Neostigmine Methylsulfate Injection can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. The incidence of malformations in human pregnancies has not been established for neostigmine as the data are limited. All pregnancies, regardless of drug exposure, h
Neostigmine Methylsulfate Injection, USP is available in 10 mL multiple dose amber glass vials containing a clear, colorless solution. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] and protect from light. Store vials in tray until ready for use. This container closure is not made with natural rubber latex.
New Drug Application
NEOSTIGMINE METHYLSULFATE- NEOSTIGMINE METHYLSULFATE INJECTION, SOLUTION FRESENIUS KABI USA, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE NEOSTIGMINE METHYLSULFATE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR NEOSTIGMINE METHYLSULFATE INJECTION. NEOSTIGMINE METHYLSULFATE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1939 INDICATIONS AND USAGE Neostigmine Methylsulfate, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery ( 1). DOSAGE AND ADMINISTRATION Dosage Should be administered by trained healthcare providers ( 2.1) Recommend use of a peripheral nerve stimulator to determine whether neostigmine methylsulfate should be administered and to monitor recovery from neuromuscular blockade ( 2.1). Recommended dosage range is 0.03 mg/kg to 0.07mg/kg for reversing nondepolarizing neuromuscular block when administered with an anticholinergic agent (atropine or glycopyrrolate) ( 2.2, 2.3, 2.4) For reversal of NMBAs with shorter half-lives, when first twitch response is substantially greater than 10% of baseline, or when a second twitch is present: 0.03 mg/kg by intravenous route ( 2.2) For reversal of NMBAs with longer half-lives or when first twitch response is close to 10% of baseline: 0.07 mg/kg by intravenous route ( 2.2) Maximum total dosage is 0.07 mg/kg or up to a total of 5 mg (whichever is less) ( 2.2) An anticholinergic agent, e.g., atropine sulfate or glycopyrrolate, should be administered prior to or concomitantly with neostigmine methylsulfate ( 2.4) Dose of Anticholinergic Agent (atropine or glycopyrrolate) Administer atropine sulfate (~15 mcg/kg) or glycopyrrolate (~10 mcg/kg) intravenously either several minutes before or concomitantly with neostigmine methylsulfate (using separate syringes) ( 2.4) DOSAGE FORMS AND STRENGTHS Injection: 0.5 mg/mL and 1 mg/mL solution in 10 mL multiple dose vial in packages of 10 via Read the complete document